(Mosquirix; GlaxoSmithKline, Belgium), in Malawi. Despite the substantial progress in the fight against this disease in the past decade, one death due to malaria still occurs every 2 min, and 2017 data 2 suggest that the decline in mortality is slowing. Other tools that could help reach the public health goals of malaria control should therefore be welcomed. 3 In this context, it is important to correctly inform on the efficacy of the RTS,S vaccine, as shown in the collective 12 000 children vaccinated in all clinical trials. In children aged 5 months or older, who were targeted for pilot implementation, four doses of the vaccine reduced clinical malaria episodes by 39% (from 1·14 cases per person-year at risk in the control group [n=2336] to 0·79 in the vaccine group [n=2276]) and life-threatening severe malaria episodes by 29% (from 135 [0·06%] cases reported in the control group to 94 [0·04%] in the vaccine group) over a 4-year follow-up period, in addition to protection provided by bednets. 4, 5 In the initial 18 months of follow-up after three primary vaccine doses, the vaccine reduced clinical malaria episodes by 46% (from 1·17 cases per person-year at risk in the control group [n=2328] to 0·69 in the vaccine group [n=4557]) and severe malaria by 36% (from 95 [0·04%] cases in the control group to 120 [0·03%] in the vaccine group). 4 In areas with high disease burden, this efficacy, although partial, could potentially result in substantial public health benefits and could help protect children when they are most vulnerable to malaria and its serious consequences.
The vaccine was reviewed by global regulatory authorities and the three countries where pilot implementation is underway (Malawi, Ghana, and Kenya), and it was approved for use in the context of the pilot implementations. The scientific community has an important role by conveying accurate clinical information.
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Deep medicine, artificial intelligence, and the practising clinician
Indra Joshi's brilliant Perspective 1 offers an in-depth analysis of Eric Topol's book, Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. However, several essential concerns about artificial intelligence (AI) in the clinic were not, or not sufficiently, addressed.
First, in primary medical practice, a major weakness of machine learning algorithms-many of which are still black boxes 2 -is the lack of explanation regarding their diagnostic and therapeutic conclusions. Replacing these algorithms' predictions with an analysis that both the clinician and the patient can understand would be a decisive breakthrough towards optimising their clinical use, especially because they also raise issues of safety, regulation, and equity of care. 3 Second, the tremendous financial implications of the health data that are fed into AI were not mentioned. As Thomas Insel noted, "If data are
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